期刊
VASA-EUROPEAN JOURNAL OF VASCULAR MEDICINE
卷 48, 期 6, 页码 461-471出版社
HOGREFE AG-HOGREFE AG SUISSE
DOI: 10.1024/0301-1526/a000787
关键词
Angiogenesis; bone marrow stem cells; cell therapy; critical lower limb ischemia; peripheral vascular disease
Cell therapy is proposed for indirect revascularization for the patient's incurable by endovascular or surgical revascularization. The therapy with stem cells (SCs) or progenitor cells is assumed to be more efficient as compared with protein or gene therapy not only because of their direct vasculogenic properties, but also thanks to their paracrine effect via secretion of manifold biologically active substances. This review gives an overview of the potential of SC-based therapy for critical limb ischemia (CLI), putative mechanism underlying cell therapy, and comparison of cell therapy to angiogenesis gene therapy in CLI treatment. Human trial data and meta-analysis, as well as some problems of clinical trials and considerations for future SC-based therapy in CLI are also discussed.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据